The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9
Abstract
The p53 gene has been implicated in many cancers due to its frequent mutations as well as mutations in other genes whose proteins directly affect p53's functions. In addition, high expression of p53 [wild-type (WT) or mutant] has been found in the cytoplasm of many tumor cells, and studies have associated these observations with more aggressive tumors and poor prognosis. Cytoplasmic mis-localization of p53 subsequently reduced its transcriptional activity and this loss-of-function (LOF) was used to explain the lack of response to chemotherapeutic agents. However, this hypothesis seemed inadequate in explaining the apparent selection for tumor cells with high levels of p53 protein, a phenomenon that suggests a gain-of-function (GOF) of these mis-localized p53 proteins. In this study, we explored whether the direct involvement of p53 in the apoptotic response is via regulation of the caspase pathway in the cytoplasm. We demonstrate that p53, when present at high levels in the cytoplasm, has an inhibitory effect on caspase-9. Concurrently, knockdown of endogenous p53 caused an increase in the activity of caspase-9. p53 was found to interact with the p35 fragment of caspase-9, and this interaction inhibits the caspase-9 activity. In a p53-null background, the high-level expression of both exogenous WT and mutant p53 increased the resistance of these cells to cisplatin, and the data showed a correlation between high p53 expression and caspase-9 inhibition. These results suggest the inhibition of caspase-9 as a potential mechanism in evading apoptosis in tumors with high-level p53 expression that is cytoplasmically localized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutated p53 inhibited the apoptosis of tumor cells with high p53 levels by inhibiting caspase-9 activity.161”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [161]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Research works printed but not linked: 54
- 10.1016/0092-8674(79)90293-9 · DOI · Paper page
- Kress M, 1979, J Virol, 31, 472, 10.1128/JVI.31.2.472-483.1979 · DOI · Paper page
- 10.1016/0042-6822(79)90250-2 · DOI · Paper page
- 10.1016/0092-8674(79)90053-9 · DOI
- 10.1038/278261a0 · DOI · Paper page
- Crook T, 1992, EMBO J, 11, 3935, 10.1002/j.1460-2075.1992.tb05487.x · DOI
- 10.1093/jnci/85.3.200 · DOI · Paper page
- 10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P · DOI
- 10.1002/path.2784 · DOI · Paper page
- 10.1073/pnas.122062299 · DOI · Paper page
- Thukral SK, 1994, Mol Cell Biol, 14, 8315, 10.1128/MCB.14.12.8315 · DOI
- 10.1093/jnci/89.20.1530 · DOI
- Bosari S, 1995, Am J Pathol, 147, 790
- 10.1073/pnas.89.15.7262 · DOI · Paper page
- 10.1073/pnas.92.10.4407 · DOI · Paper page
- 10.1016/0959-8049(94)90082-5 · DOI
- 10.1016/0140-6736(92)92558-W · DOI · Paper page
- 10.1111/j.1600-0463.2008.00917.x · DOI
- Ghavam-Nasiri MR, 2007, Arch Iran Med, 10, 38
- Guillou L, 1996, Am J Pathol, 149, 1221
- 10.4161/cc.7.19.6751 · DOI · Paper page
- 10.1038/nchembio.546 · DOI · Paper page
- 10.1016/j.ccr.2011.06.004 · DOI · Paper page
- Martynova E, 2012, Oncotarget, 3, 132, 10.18632/oncotarget.447 · DOI
- 10.4161/cbt.11.8.14906 · DOI · Paper page
- 10.1146/annurev.biochem.68.1.383 · DOI · Paper page
- 10.1038/sj.cdd.4400536 · DOI · Paper page
- 10.1038/bjc.1992.273 · DOI · Paper page
- 10.1073/pnas.132241599 · DOI · Paper page
- 10.1158/1535-7163.MCT-06-0336 · DOI · Paper page
- Wei MC, 2000, Genes Dev, 14, 2060, 10.1101/gad.14.16.2060 · DOI · Paper page
- 10.1074/jbc.M003670200 · DOI · Paper page
- 10.1016/S1097-2765(03)00054-6 · DOI · Paper page
- 10.1038/40901 · DOI · Paper page
- 10.1038/35065125 · DOI · Paper page
- 10.1016/S1097-2765(00)80095-7 · DOI · Paper page
- 10.1084/jem.187.4.587 · DOI · Paper page
- 10.1038/sj.cdd.4401065 · DOI · Paper page
- 10.1074/jbc.273.42.27084 · DOI · Paper page
- 10.1073/pnas.0712034105 · DOI
- 10.4161/cc.10.1.14365 · DOI
- 10.1182/blood-2009-12-256149 · DOI
- 10.1016/S0092-8674(00)00073-8 · DOI · Paper page
- Stenger JE, 1994, EMBO J, 13, 6011, 10.1002/j.1460-2075.1994.tb06947.x · DOI · Paper page
- 10.1038/387299a0 · DOI · Paper page
- 10.1099/0022-1317-36-1-59 · DOI · Paper page
- König C, 1999, J Virol, 73, 2253, 10.1128/JVI.73.3.2253-2262.1999 · doi:10.1128/jvi.73.3.2253-2262.1999
- Blair Zajdel ME, 1988, Oncogene, 2, 579
- 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
- 10.1016/S0092-8674(00)80434-1 · DOI · Paper page
- 10.4161/cc.11.5.19447 · doi:10.4161/cc.11.5.19447
- Blagosklonny MV, 2012, Oncotarget, 3, 601, 10.18632/oncotarget.548 · DOI
- 10.1016/S0301-4622(02)00011-X · DOI
- 10.1158/1078-0432.CCR-10-1587 · DOI · Paper page
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
A Review on Caspases: Key Regulators of Biological Activities and Apoptosis
Sahoo, G., Samal, D., Khandayataray, P., & Murthy, M. K. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03433-5 · Cited by 387
Clinical Overview of MDM2/X-Targeted Therapies
Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315
Caspase-9: structure, mechanisms and clinical application
Li, P., Zhou, L., Zhao, T., Liu, X., Zhang, P., Liu, Y., Zheng, X., & Li, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.15098 · Cited by 319
Deoxynivalenol induced apoptosis and inflammation of IPEC-J2 cells by promoting ROS production
Kang, R., Li, R., Dai, P., Li, Z., Li, Y., & Li, C. (2019) · Environmental Pollution · doi:10.1016/j.envpol.2019.05.026 · Cited by 289
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Chee, J. L. Y., Saidin, S., Lane, D. P., Leong, S. M., Noll, J. E., Neilsen, P. M., Phua, Y. T., Gabra, H., & Lim, T. M.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2013-01-15
- Volume
- 12
- Issue
- 2
- Pages
- 278-288
- ISSN
- 1538-4101
- 1551-4005
- Cited by
- 63
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.